STAT+: Prime wins Beam arbitration, clearing path to clinic
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A father fights to create and then save his daughter’s gene therapy, the White House nears a decision on an FDA chief, and the Trump administration pushes drugmakers to reshore generics manufacturing. A quest to save Grace — and help rare disease patients everywhere With $70 million and seemingly every fiber of his being, Matt Wilsey built a gene therapy company from scratc...
Read full article →